Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.

BMC Cancer · 2018 · PMC6020418 · PMID 29945562

Europe PMC DOI

hedged sentence

0.0031

closest p · 0.1× alpha

0.0031

boldest claim

The sentences

a significant trendp = 0.0031actually significant

Looking specifically at line of advanced disease therapy, there was a significant trend to longer PFS ( p = 0.0031 ) and OS ( p = 0.0002 ) for patients receiving nal-IRI + 5-FU/LV in earlier lines of therapy, compared with later (Fig. 2 ).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.